Biocon’s step down subsidiary -- Biocon Sdn. Bhd., Malaysia has collaborated with Voluntis to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The licensing agreement will make Biocon Sdn. Bhd subsidiary of Biocon Biologics India one of the first insulins companies to offer a U.S. Food and Drug Administration-cleared and CE-marked, highly validated digital therapeutic product, Insulia, to Type 2 diabetes patients, across several markets in the world.
Insulia provides automated insulin dose recommendations enabling people with diabetes to self-manage their condition and healthcare teams to remotely monitor progress. Insulia is the first digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of basal insulins.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
